A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors

Nelfinavir is an HIV protease inhibitor being repurposed as an anti-cancer agent in preclinical models and in small oncology trials, yet the MTD of nelfinavir has not been determined. Therefore, we conducted a Phase Ia study to establish the maximum tolerated dose (MTD) and dose limiting toxicities...

Descripción completa

Detalles Bibliográficos
Autores principales: Blumenthal, Gideon M., Gills, Joell J., Ballas, Marc S., Bernstein, Wendy B., Komiya, Takefumi, Dechowdhury, Roopa, Morrow, Betsy, Root, Hyejeong, Chun, Guinevere, Helsabeck, Cynthia, Steinberg, Seth M., LoPiccolo, Jaclyn, Kawabata, Shigeru, Gardner, Erin R., Figg, William D., Dennis, Phillip A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226674/
https://www.ncbi.nlm.nih.gov/pubmed/25327558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226674/
https://www.ncbi.nlm.nih.gov/pubmed/25327558

Ejemplares similares